To explore the effect of sudan I, III, and IV on the DNA/RNA ratio and changes in the 3D structure of HepG-2. LCM and 3D images are used to detect the DNA/RNA ratio and changes in the 3D structure of HepG-2 when treat...To explore the effect of sudan I, III, and IV on the DNA/RNA ratio and changes in the 3D structure of HepG-2. LCM and 3D images are used to detect the DNA/RNA ratio and changes in the 3D structure of HepG-2 when treated with different dosages of sudan I, III, and IV. The DNA/RNA ratio of the control group is 1.223 2±0.084 4, while the fluorescence intensity of DNA in HepG-2 treated with sudan I, III, or IV is markedly greater than that of RNA, with the low-dosage group showing significant effect (P<0.01), yielding DNA/RNA ratios of 1.609 6±0.199 0, 1.445 5±0.163 3, 1.708 1±0.109 0 respectively; 3D images show that DNA fluorescence in HepG-2 is mostly concentrated in the nuclear region, and is denser and stronger than RNA fluorescence. The DNA/RNA ratio of a treated group increases after being treated with different dosages of sudan, but it declines with increasing dosage, and within a certain dosage range, sudan I, III, and IV are shown to promote the growth of HepG-2.展开更多
文摘To explore the effect of sudan I, III, and IV on the DNA/RNA ratio and changes in the 3D structure of HepG-2. LCM and 3D images are used to detect the DNA/RNA ratio and changes in the 3D structure of HepG-2 when treated with different dosages of sudan I, III, and IV. The DNA/RNA ratio of the control group is 1.223 2±0.084 4, while the fluorescence intensity of DNA in HepG-2 treated with sudan I, III, or IV is markedly greater than that of RNA, with the low-dosage group showing significant effect (P<0.01), yielding DNA/RNA ratios of 1.609 6±0.199 0, 1.445 5±0.163 3, 1.708 1±0.109 0 respectively; 3D images show that DNA fluorescence in HepG-2 is mostly concentrated in the nuclear region, and is denser and stronger than RNA fluorescence. The DNA/RNA ratio of a treated group increases after being treated with different dosages of sudan, but it declines with increasing dosage, and within a certain dosage range, sudan I, III, and IV are shown to promote the growth of HepG-2.
